Two Sigma Investments LP bought a new stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 437,500 shares of the company's stock, valued at approximately $4,358,000. Two Sigma Investments LP owned about 1.95% of Oaktree Acquisition Corp. III Life Sciences as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Lighthouse Investment Partners LLC bought a new position in Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $3,039,000. Toronto Dominion Bank acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at $14,355,000. Sculptor Capital LP acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at $2,490,000. Shaolin Capital Management LLC acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at $5,478,000. Finally, AQR Arbitrage LLC acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth $19,743,000.
Oaktree Acquisition Corp. III Life Sciences Trading Up 0.1%
Shares of OACC stock traded up $0.01 on Monday, hitting $10.45. The company had a trading volume of 1,220 shares, compared to its average volume of 116,979. The company's 50-day moving average price is $10.29. Oaktree Acquisition Corp. III Life Sciences has a twelve month low of $9.95 and a twelve month high of $10.85.
Oaktree Acquisition Corp. III Life Sciences Company Profile
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Featured Stories
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
